Stay updated on Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial
Sign up to get notified when there's something new on the Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial page.

Latest updates to the Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe NAMSAL study record is now available, detailing a completed Phase 3 trial comparing dolutegravir- and efavirenz-based regimens for adults with HIV-1 in Cameroon, along with study criteria, outcomes, locations, and publications.SummaryDifference62%

- Check21 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 Forbidden page.SummaryDifference0.2%

- Check28 days agoChange DetectedThe study record is now displayed, including its treatment arms, eligibility criteria, locations, outcomes, and publication history, rather than an access-denied error.SummaryDifference65%

- Check35 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1, while the page continues to show a 403 error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study page now displays a 403 error page, replacing the previous content with an access-restricted view.SummaryDifference21%

Stay in the know with updates to Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dolutegravir for Initial HIV in Resource-limited Settings Clinical Trial page.